Canada Pension Plan Investment Board Has $55.26 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Canada Pension Plan Investment Board decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 9.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 413,492 shares of the life sciences company's stock after selling 41,150 shares during the period. Canada Pension Plan Investment Board owned 0.26% of Illumina worth $55,255,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Farringdon Capital Ltd. bought a new stake in shares of Illumina in the 4th quarter valued at $206,000. Zacks Investment Management boosted its position in shares of Illumina by 3.5% during the 4th quarter. Zacks Investment Management now owns 23,210 shares of the life sciences company's stock worth $3,102,000 after purchasing an additional 786 shares in the last quarter. Jump Financial LLC grew its stake in shares of Illumina by 260.0% in the 4th quarter. Jump Financial LLC now owns 7,865 shares of the life sciences company's stock valued at $1,051,000 after buying an additional 5,680 shares during the period. Senvest Management LLC increased its position in Illumina by 19.5% in the 4th quarter. Senvest Management LLC now owns 1,070,292 shares of the life sciences company's stock valued at $143,023,000 after buying an additional 174,532 shares in the last quarter. Finally, Canada Post Corp Registered Pension Plan acquired a new position in Illumina during the 4th quarter worth approximately $8,852,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Wall Street Analyst Weigh In

ILMN has been the subject of several recent research reports. Hsbc Global Res downgraded Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Royal Bank of Canada dropped their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. Barclays lowered their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a report on Thursday, April 10th. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a research note on Friday, February 28th. Finally, TD Cowen lowered Illumina from a "buy" rating to a "hold" rating and lowered their price target for the company from $177.00 to $140.00 in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Illumina has an average rating of "Moderate Buy" and an average target price of $138.70.

Illumina Stock Down 3.2 %

ILMN stock opened at $71.21 on Friday. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The stock has a fifty day moving average of $84.61 and a 200-day moving average of $120.40. The company has a market capitalization of $11.27 billion, a price-to-earnings ratio of -9.27, a PEG ratio of 1.60 and a beta of 1.38. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.